861841-94-3

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-(Benzyloxy)-2-hydroxy-3-nitrophenyl)ethanone is used as a key intermediate in the synthesis of Olodaterol (O262000), a novel inhaled β2-adrenoceptor agonist. 1-(5-(benzyloxy)-2-hydroxy-3-nitrophenyl)ethanone exhibits a 24-hour bronchodilatory efficacy, making it a valuable component in the development of long-acting asthma and chronic obstructive pulmonary disease (COPD) treatments.
As an intermediate, 1-(5-(Benzyloxy)-2-hydroxy-3-nitrophenyl)ethanone plays a crucial role in the production of Olodaterol, which is designed to provide sustained relief for respiratory conditions. Its unique structure allows for the formation of the final drug product through a series of chemical reactions, ultimately leading to a medication that can improve the quality of life for patients suffering from respiratory ailments.

InChI:InChI=1S/C15H13NO5/c1-10(17)13-7-12(8-14(15(13)18)16(19)20)21-9-11-5-3-2-4-6-11/h2-8,18H,9H2,1H3

Upstream product

• 30992-63-3 5-benzyloxy-2-hydroxyacetophenone 
• 100-39-0 benzyl bromide 
• 490-78-8 2,5-Dihydroxyacetophenone 

Downstream Products

• 861841-93-2 trifluoromethansulfonic acid 2-acetyl-4-benzyloxy-6-nitro-phenyl ester 
• 869478-09-1 8-acetyl-6-(phenylmethoxy)-4H-1,4-benzoxazin-3-one 
• 926319-53-1 8-(bromoacetyl)-6-(phenylmethoxy)-2H-1,4-benzoxazin-3(4H)-one 
• 869478-12-6 8-(2R)-oxirane-6-(phenylmethoxy)-2H-1,4-benzoxazine-3(4H)-one 
• 861841-90-9 1-[2-hydroxy-3-amino-5-(benzyloxy)phenyl]ethanone 

Relevant academic research and scientific papers

CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE

The invention provides a class of compounds represented by formula (I), having bifunctional active quaternary ammonium salt structure of a β2-adrenoreceptor agonist and an M receptor antagonist, a pharmaceutically acceptable salt, solvate, and optical isomer thereof. A pharmaceutical composition comprising such a compound with quaternary ammonium salt structure, a method for preparing such a compound with quaternary ammonium salt structure and an intermediate thereof, and uses thereof in treating pulmonary disorders are also provided. The compounds of the invention have high selectivity to the M receptor subtype, and have less adverse reaction and lower toxic and side effects in the treatment of pulmonary diseases such as COPD and asthma.

Benzoxazine compound and its preparation methods and application

The invention relates to a benzoxazine compound represented in the following formula 1. The benzoxazine compound can serve as a beta 2 receptor agonist. The formula can be seen from the description.

PROCESS FOR THE MANUFACTURING OF BETA MIMETICS

The invention relates to a method for producing betamimetics of formula (1), wherein in which n represents 1 or 2; R1 represents hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl; R2 represents hydrogen, halogen, C

Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacy

Compound 4p was identified from a series of 6-hydroxy-4H-benzo[1,4]oxazin-3-ones as potent agonist of the human β2-adrenoceptor with a high β1/β2-selectivity. A complete reversal of acetylcholine-induced bronchoconstrictio

PROCESS FOR THE MANUFACTURING OF BETAMIMETICS

The present invention relates to a process for preparing betamimetics of formula 1, wherein n denotes 1 or 2; R1 denotes hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl; R2 denotes hydrogen, halogen, C1-4/su

Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof

The present invention relates to enantiomerically pure compounds of formula 1 wherein the groups m, n, B, X, R1, m and Ym- may have the meanings given in the claims and specification, methods for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

Medicament Combinations for the Treatment of Respiratory Diseases

The present invention relates to new medicament combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein A, B, R1, X, n and m may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

New betamimetics for the treatment of respiratory complaints

The present invention relates to compounds of formula 1 wherein the groups n, m, B, X and R1 may have the meanings given in the claims and specification, processes for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments

The present invention relates to enantiomerically pure compounds of general formula 1 wherein the groups R1, R2, R3, R4 and X? may have the meanings given in the claims and in the specification, proce

NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG

The invention relates to enantiomerically pure compounds of formula (1), wherein the radicals R1, R2, R3, R4and X are defined as in claims and a description. A method for producing said compounds and the use thereof